- Despite failing to demonstrate a beneficial effect over and above standard-of-care treatment in an NIAID-sponsored study, Eli Lilly (NYSE:LLY) inked an initial agreement with the U.S. government to supply 300K vials of neutralizing antibody bamlanivimab (LY-CoV555) 700 mg for $375M contingent on an FDA emergency use nod. The company submitted its EUA request earlier this month for treating mild-to-moderate COVID-19 in high-risk patients.
- The initial deal is for delivery over two months following EUA with an option to buy an additional 650K vials through June 30, 2021.
- Lilly expects to manufacture up to 1M doses by year-end for global use. Production will ramp significantly next year.
- Talks with global regulators are ongoing.
https://seekingalpha.com/news/3627067-lilly-inks-u-s-deal-to-supply-300k-vials-of-ly-cov555-for-covidminus-19
Wednesday, October 28, 2020
Lilly inks U.S. deal to supply 300K vials of LY-CoV555 for COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.